` 6919 (Caliway Biopharmaceuticals Co Ltd) vs Taiwan Weighted Index Comparison - Alpha Spread

6919
vs
Taiwan Weighted Index

Over the past 12 months, has significantly outperformed Taiwan Weighted Index, delivering a return of 39% compared to the Taiwan Weighted Index's 0% drop.

Stocks Performance
6919 vs Taiwan Weighted Index

Loading
6919
Taiwan Weighted Index
Add Stock
www.alphaspread.com

Performance Gap
6919 vs Taiwan Weighted Index

Loading
6919
Taiwan Weighted Index
Difference
www.alphaspread.com

Performance By Year
6919 vs Taiwan Weighted Index

Loading
6919
Taiwan Weighted Index
Add Stock

Competitors Performance
Caliway Biopharmaceuticals Co Ltd vs Peers

Taiwan Weighted Index
6919
LLY
JNJ
NOVO B
ROG
Add Stock

Caliway Biopharmaceuticals Co Ltd
Glance View

Market Cap
133.6B TWD
Industry
Pharmaceuticals

Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.

Intrinsic Value
437.15 TWD
Overvaluation 49%
Intrinsic Value
Price
C
Back to Top